A Study of REC-4881 in Participants with Cancers Which Have an AXIN1 or APC Mutation
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.